

Batch Certificate For Research Use Only

PRODUCT INFORMATION AND QUALITY CONTROL				
NAME OF PRODUCT	5-Gene-Multiplex 1% AF cfDNA in Plasma			
	AKT1/BRAF/ERBB2/KRAS/PIK3CA			
DESCRIPTION	Human proteins in common plasma concentrations, electrolytes,			
	EDTA, cfDNA / ctDNA in common plasma concentrations			
CATALOG NUMBER	SID-00089			
BATCH NUMBER	00027			
MANUFACTURING	Manufactured and sealed in class 2 safety cabinet			
CONDITIONS	Bottled with qualified liquid handling workstation			
	At room temperature			
PACKAGE SIZE AND	2D barcoded tube with screw cap			
TYPE	Material: Polypropylen (PP)			
DATE OF MANUFACTURE	12.11.2019			
EXPIRY DATE	11.11.2021			
CONCENTRATION	80 ng/ml (ds DNA)			
QUANTITY	400 ng (ds DNA)			
NOMINAL VOLUME	20.1μl in 5 ml plasma			
MUTATION	AKT1 p.E17K (COSM33765*, COSV62571334*, substitution, c.49G>A, Exon 2)			
	BRAF p.V600E (COSM476*, COSV56056643*, substitution, c.1799T>A, Exon 15)			
	ERBB2 p.E770_A771insAYVM (new: p.Y772_A775dup) (COSM20959*/ COSM404915*, COSV54062409*, insertion, c.2313_2324dup/ c.2310_2311ins12, Exon 19)			
	KRAS p.G12D (COSM521*, COSV55497369*, substitution, c.35G>A, Exon 1)			
	KRAS p.Q61K (COSM549*, COSV55502066*, substitution, c.181C>A, Exon 2)			
	KRAS p.A146T (COSM19404*, COSV55501778*, substitution, c.436G>A, Exon 3) PIK3CA p.H1047R (COSM775*, COSV55873195*, substitution, c.3140A>G, Exon 20)			
	PIK3CA p.E545K (COSM7/53*, COSV55873239* substitution, c.1633G>A, Exon 9)			
	* GRCh38 COSMIC v90			
ALLELIC FREQUENCY	1%			
QUALITY	DNA quantity metrologically traceable to internationally certified			
	reference material ¹ The copy number values are metrologically traceable to the			
	natural units count 1 and ratio 1 and International System of Units			
	(SI) derived units of volume.			
STORAGE CONDITIONS	+ 2-8 °C			



MANUFACTURING AND	SensID GmbH				1 dgC 2/ J	
QUALITY CONTROL	Schillingallee 68, 18057 Rostock, Germany					
SITES						
TEST METHOD AND	Quality Control	Test Method	Acceptance			
ACCEPTANCE CRITERIA			criteria			
		Fragment Length Analysis ²		peak size 167 bp		
	Fragmentation	Agilent High Sensitivity DNA Kit		± 10%		
		(Agilent Technologies)		(151 bp – 181 bp)		
		Total DNA measurement: Spectrophotometry		ssDNA:		
				n.a. ⁴		
	Quantification	ssDNA [ng/µl] = (A260-A320)*38 ^{2,3}				
		dsDNA measurement ² : Qu	ırement ² : Qubit		dsDNA:	
		dsDNA BR Assay Kit (Invitrogen)		n.a. ⁴		
	Allelic	dPCR Analysis ²		AF 1% ±40%		
	Frequency	using BioRad QX200™ System		(0.6–1.4%)		
RESULTS OF ANALYSIS		Result			PASS/FAIL	
	Fragmentation	181 bp			PASS	
		30.2 ng/µl (total DNA)				
	Quantity	19.9 ng/µl (dsDNA)				
		MutationAF iAKT1 E17K1.BRAF V600E0.				
					-	
		ERBB2				
	Allelic	E770_A771insAYVM (Y772_A775dup)	1.	.1	PASS	
	Frequency	KRAS G12D	_	.1		
		KRAS Q61K KRAS A146T		.1		
		PIK3CA H1047R		0		
COMMENTS/REMARKS	Additional inform	PIK3CA E545K	0	.8		
			ements			
	Copy numbers (CN) of the respective measurements Table 1 indicates the values of the QC assays performed by SensID GmbH with an DNA input					
		$f \sim 40$ ng. The value for the respective mutation results from the mean value of three				
	measured replicates (CN values are rounded). CN concentration values per microlite are based on droplet digital (ddPCR) assay counts dilution factors, and droplet va					
	measurements. The detection of the amount of CNs may vary depending on the assay					

² Measured before spiking in ³ Protocol NK603 – Community Reference Laboratory for GM Food and Feed ⁴not applicable **Phone:** +49 (0) 381 377 182 01 **Net:** <u>www.sens-id</u>

Net: <u>www.sens-id.com</u> SensID GmbH, Schillingallee 68, 18057 Rostock, Germany

Mail: support@sens-id.com



Therefore, due to assay properties, there may be deviations in the observed number of copies and allele frequencies compared to the values given here.

Mutation	CN wt⁵/µl	CN mut⁰/µl
AKT1 E17K	2152	25
BRAF V600E	1805	17
ERBB2 E770_A771insAYVM (Y772_A775dup)	3055	34
KRAS G12D	2821	33
KRAS Q61K	3180	37
KRAS A146T	3946	39
PIK3CA H1047R	3748	38
PIK3CA E545K	2401	21

Name and position/title of Person authorising the batch release:

Mr. Björn Nowack, Managing Director

Date of batch release: 12.11.2019

Signature batch release: Björn Nowack

This document was created electronically and is valid without a signature.